Radiopharmaceuticals: Market Research Report

December 2018 | 310 pages | ID: R6F15184084EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Thousand by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin America.

Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 61 companies including many key and niche players such as -

• Actinium Pharmaceuticals, Inc.
• Alliance Medical
• Alseres Pharmaceuticals, Inc.
• Avid Radiopharmaceuticals
• Bayer HealthCare Pharmaceuticals
• Bracco Diagnostics, Inc.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
A. Diagnostic Radiopharmaceuticals
B. Therapeutic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Prelude
Current & Future Analysis
Diagnostic Radiopharmaceuticals: The Dominant Segment
Select Cardiology and Oncology Radiopharmaceuticals
New Therapeutic Radiopharmaceuticals to Drive Global Market
Market Drivers
Growing Acceptance in Cancer Treatment
Increasing Acceptance of Disease-Targeted Treatment
Growing Emphasis of Accurate Diagnosis
Expanding Molecular Imaging Applications
Market Restraints
Stringent Regulatory Guidelines for Manufacture, Storage and Usage
Global Supply Shortages
Price Sensitivity & Competition from Alternatives
Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
Unfounded Fears of Radiation Exposure Hinder Growth
Bottlenecks in Developing Markets
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
Competition
Relevant Aspects of Radiopharmaceutical Production
Increasing Uptake of PET: A Prime Growth Driver
Non-Reactor Based TC-99m Production to Drive SPECT Growth
New Radiopharmaceuticals Drive Adoption of Molecular Imaging
PET and SPECT in Cardiovascular Imaging
Innovative Radiotracers – Key to PET & SPECT Success in Cardiovascular Imaging
Cardiac Amyloidosis Visualization – A Potential Application for PET
Application of PET in Drug Development to Expand Opportunities
Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic Benefits
Innovative Radiopharmaceuticals to Boost Cardiac Applications
Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
Personalized Medicine to Drive Nuclear Medicine

Table 1. Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)

Rise in Incidence of Neurological Disorders to Drive Growth
Battling Alzheimer’s Disease – A Powerful Market Force for Nuclear Medicine
Combating the Shortage of RadioIsotopes

2. LONGSTANDING GROWTH DRIVERS

Rise in Incidence of Cancer – A Major Growth Driver
Cancer Prone Sites based on Age

Table 2. Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart)

Ageing Population – A Vital Demography

Table 3. Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)

Table 4. Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)

Global CVD Stats

Table 5. Global Estimated Fatalities by Heart Conditions - Percentage Share Breakdown for Ischemic Heart Disease, Stroke, CVD, and Others (includes corresponding Graph/Chart)

Table 6. Projected Fatalities in Low Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)

Table 7. Projected Fatalities in Mid Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart)

3. PRODUCT OVERVIEW

Radiopharmaceuticals: A Definition
Mechanism of Action
Application of Radiopharmaceuticals
Radioactive Tracers for Diagnostic Imaging
Therapeutics
Research
Sterilization
Classification of Radiopharmaceuticals
Diagnostic Radiopharmaceuticals
Commonly Used Diagnostic Radiopharmaceutical Agents
Major Isotopes and their Diagnostic Applications
Advantages
Classification
Cardiology Diagnostics
Non-cardiology Diagnostics
Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
Planar Imaging
Positron Emission Tomography (PET)
Applications of PET
Commonly used Radioisotopes in PET Scans
Major PET Isotopes and their Applications
Single Photon Emission Computed Tomography (SPECT)
Applications of SPECT
Commonly used Radioisotopes in SPECT Scans
Therapeutic Radiopharmaceuticals
Characteristics of Therapeutic Radiopharmaceuticals
Commonly used Therapeutic Agents
Major Isotopes and their Therapeutic Applications
Note on Select Commercially Available Therapeutic Radiopharmaceuticals

4. PRODUCT INNOVATIONS/INTRODUCTIONS

ORA Launches NEPTIS xSeed Kitless Synthesizer
Advanced Accelerator Applications Resubmits NDA for Lutathera
Norgine B. V. Launches LYMPHOSEEK
IBA launches the Fixed IFP
Piramal Imaging and ISOLOGIC Innovative Radiopharmaceuticals Receive Approval
FDA Approves Netspot to Detect Rare Neuroendocrine Tumors
Blue Earth Diagnostics Bags FDA Approval for AxuminTM
EMA Issues Positive Opinion on Marketing Authorization Application for SomaKit TOC
IBA Unveils the Cyclone KIUBE Cyclotron
Advanced Accelerator Expands NETSPOTTM Supply Chain
Blue Earth Diagnostics and Siemens’ PETNET Solutions Introduce AxuminTM (Fluciclovine F 18) Injection
Blue Earth Wins FDA Approval for PET Agent for Axumin
Zevacor to Develop SomaKit-TATE doses for AAA
Triad Isotopes Receives FDA Approval for Fludeoxyglucose F18 (18F FDG) and Sodium Fluoride F-18.
Zevacor Wins FDA Approval of ANDA for Choline C11
Advanced Medical Isotope Receives FDA Clearance for Y-90 RadioGel Device
Sumitomo Heavy Industries Receives Medical Device Approval for MPS200Aβ
NorthStar Medical Radioisotopes to Start Production of Molybdenum-99
GE Healthcare Launches GENtraceTM and FASTlab 2 for Radiopharmaceutical Manufacturing
RadioMedix Introduces SmartMedix Synthesizers
Lantheus Medical Imaging Gains FDA Approval for manufacturing NEUROLITE at Jubilant HollisterStier

5. RECENT INDUSTRY ACTIVITY

Telix Pharmaceuticals and ANMI Enter into Partnership for Commercialization of ANMI’s 68Ga-HBED-CC-PSMA Kit
Telix Pharmaceuticals Signs Technology Licensing Agreement and Research Collaboration with the University of Melbourne
RadioMedix and ITM Enhter into Partnership Agreement for Distribution of Lutetium-177 in North America
Blue Earth Diagnostics Signs Exclusive Distribution Agreement with Seibersdorf Laboratories for the supply of Axumin
Blue Earth Diagnostics and GE Healthcare Sign Agreement to Manufacture Axumin
IRE-ELiT Signs Exclusive Long-Term Contract with Cardinal Health
Jubilant Acquires Radiopharmacy Business of Triad
ARTMS Products and GE Healthcare Partner to Expand Cyclotron-Produced Radioisotopes
Theragnostics Signs Partnership Agreement with ROTOP
Cyclotek and Telix Pharmaceuticals Sign Radiopharmaceutical Manufacturing Agreement
IBA and Philips Collaborate for Sales and Marketing of Proton Therapy in Brazil
Advanced Accelerator Applications Signs Agreement with Blue Earth Diagnostics to Supply Axumin
ARTMS Products Partners with Alliance Medical to Supply Tc-99m
Sofie Biosciences to Acquire Zevacor Pharma
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Form Curium
GE Healthcare to Supply Radiopharmaceuticals to HealthTrust
IBA Signs Co-Marketing Agreement in North America with Nelco Worldwide
Telix Announces Product Development Partnership with Therapeia
IBA Signs ProteusONE Contracts with Proton Partners International
Cellectar Biosciences Selects Hamilton for Supply of CLR
Life Healthcare Acquires Alliance Medical Group
Lantheus Holdings Divests its Australian Radiopharmacy Servicing Business
ITEL Signed Agreement with AAA to Manufacture and Commercialize F-18 Radiopharmaceuticals
Zevacor Pharmato Manufacture and Supply Lomab-B for Pivotal Phase 3 SIERRA Trial
Blue Earth Diagnostics and Norsk Enter into Manufacturing and Distribution partnership for Fluciclovine (18F)
Ipsen and 3B Pharmaceuticals Sign Exclusive License Agreement to Develop Novel Radiopharmaceuticals in Oncology
Isologic Acquires Lantheus Medical Imaging Canadian Radiopharmaceutical Business
IRE ELiT & Monrol Sign Distribution Agreement for Galli Eo
Westinghouse Signs Agreement with NorthStar for Production of Medical Radioisotopes
Advanced Medical Enters into Collaboration with IsoTherapeutics to
ISOLOGIC Opens New Cyclotron and Radiopharmaceutical Manufacturing Facility
IBA Divests IBA Molecular North America Business to Illinois Health and Science
AAA Enters into Distribution Agreement with FUJIFILM RI Pharma for Lutathera in Japan
Piramal Imaging Signs Strategic Partnership with ISOLOGIC for Exclusive Commercialization of Neuraceq in Canada
Ipsen to Acquire OctreoPharm Sciences
RadioMedix Enters into agreement with AREVA Med to Develop a Novel Treatment against Neuroendocrine Tumors
Siemens’ PETNET Solutions to Manufacture and Distribute Blue Earth’s Fluciclovine (18F)
IBA to Sell U. S. Operations to Illinois Health and Science
Lantheus Medical Signs agreement with IRE for supply of Xenon Xe 133 Gas
INR Receives U. S. Patent for Radiostrontium Production Technology

6. FOCUS ON SELECT PLAYERS

Actinium Pharmaceuticals, Inc. (USA)
Alliance Medical (UK)
Alseres Pharmaceuticals, Inc. (USA)
Avid Radiopharmaceuticals (USA)
Bayer HealthCare Pharmaceuticals (Germany)
Bracco Diagnostics, Inc. (USA)
Cardinal Health, Inc. (USA)
GE Healthcare (UK)
Ion Beam Applications S. A (Belgium)
Immunomedics, Inc. (USA)
Jubilant Pharma (India)
Lantheus Medical Imaging Inc. (USA)
Medi-Radiopharma Ltd (Hungary)
Nordion, Inc. (Canada)
Peregrine Pharmaceuticals, Inc. (USA)
PETNET Solutions Inc. (USA)
Positron Corporation (USA)
Triad Isotopes, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Table 8. World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 9. World Historic Review for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10. World 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 11. World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 12. World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13. World 14-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 14. World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 15. World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16. World 14-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Outlook
Radioisotope/Radiopharmaceuticals Production Scenario
Rise in Diagnostic Applications Stimulate Future Growth

Table 17. US Market for Diagnostic Radiopharmaceuticals by Modality (2016): Percentage Breakdown of Value Sales for PET and SPECT (includes corresponding Graph/Chart)

Table 18. US Market for Diagnostic Radiopharmaceuticals Agents (2016): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)

Demographic Changes Offer Growth Opportunities

Table 19. North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Rising Incidence of Cancer - A Major Growth Driver

Table 20. New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

Cardiovascular Imaging to Lead Volume Growth
Focused R&D Efforts to Fuel Therapeutic Radiopharmaceuticals Market
Radiopharmaceuticals in PET Imaging – Prospects
Isotope Shortage Leads to Dependence on Imports
US Fluorodeoxyglucose (FDG) Market
Product Launches
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 21. US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 22. US Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 23. US 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Outlook
Canadian Scientists Gear up to find Remedy for Mo-99 Supply Shortages
An Overview of Medical Imaging Market
Regulatory and Legal Restrictions
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 24. Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 25. Canadian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 26. Canadian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Outlook
Healthcare in Japan
Strategic Corporate Developments
B. Market Analytics

Table 27. Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 28. Japanese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 29. Japanese 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Outlook
New Applications and Products Augur Good Market Prospects
B. Market Analytics

Table 30. European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 31. European Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 32. European 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 33. European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 34. European Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 35. European 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Outlook
Strategic Corporate Developments
B. Market Analytics

Table 36. French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 37. French Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 38. French 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Outlook
Strategic Corporate Developments
Key Player
B. Market Analytics

Table 39. German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 40. German Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 41. German 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis
Outlook
Strategic Corporate Development
B. Market Analytics

Table 42. Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 43. Italian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 44. Italian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Outlook
Strategic Corporate Development
Select Players
B. Market Analytics

Table 45. UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 46. UK Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 47. UK 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 48. Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 49. Spanish Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 50. Spanish 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4F. RUSSIA

A. Market Analysis
Outlook
B. Market Analytics

Table 51. Russian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 52. Russian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 53. Russian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

A. Market Analysis
Outlook
Market Overview
Product Innovations/Introductions
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 54. Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 55. Rest of Europe Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 56. Rest of Europe 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Outlook
B. Market Analytics

Table 57. Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 58. Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 59. Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for China, India and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 60. Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 61. Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 62. Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5A. CHINA

Market Analysis

Table 63. Chinese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 64. Chinese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 65. Chinese 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
Outlook
Key Player
B. Market Analytics

Table 66. Indian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 67. Indian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 68. Indian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5C. REST OF ASIA-PACIFIC

A. Market Analysis
Outlook
Strategic Corporate Development
Key Player
B. Market Analytics

Table 69. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 70. Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 71. Rest of Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. MIDDLE EAST & AFRICA

Market Analysis

Table 72. Middle East & Africa Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 73. Middle East & Africa Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 74. Middle East & Africa 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7. LATIN AMERICA

A. Market Analysis
Outlook
B. Market Analytics

Table 75. Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 76. Latin American Historic Review for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 77. Latin American 14-Year Perspective for Radiopharmaceuticals by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

Table 78. Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 79. Latin American Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 80. Latin American 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7A. BRAZIL

A. Market Analysis
Outlook
Strategic Corporate Development
B. Market Analytics

Table 81. Brazilian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 82. Brazilian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 83. Brazilian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

7B. REST OF LATIN AMERICA

Market Analysis

Table 84. Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 85. Rest of Latin America Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 86. Rest of Latin America 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 61 (including Divisions/Subsidiaries - 69)
The United States (27)
Canada (4)
Japan (1)
Europe (28)
  France (4)
  Germany (5)
  The United Kingdom (4)
  Italy (2)
  Rest of Europe (13)
Asia-Pacific (Excluding Japan) (8)
Africa (1)